Parkinson Disease Psychosis Clinical Trial
Official title:
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams.
Hallucinations and memory impairment have a parallel clinical course in Parkinson's disease (PD) and are independently associated dysfunction and pathology accumulation in hippocampal subregions. Similar alterations of hippocampal function are found in schizophrenic patients with memory impairment and positive psychotic symptoms. These findings suggest that dysfunction of the hippocampus may be a shared mechanism for memory impairment and psychosis across diseases. This investigation aims to address these questions and assess the efficacy of AGB101 for the treatment of psychosis in PD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03152292 -
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
|
||
| Withdrawn |
NCT05344365 -
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
|
Phase 2 | |
| Recruiting |
NCT05357612 -
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
|
Phase 4 | |
| Completed |
NCT04292223 -
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
|
Phase 4 | |
| Completed |
NCT02969369 -
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
|
Phase 2 | |
| Not yet recruiting |
NCT05995782 -
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
|
Phase 1 | |
| Recruiting |
NCT04579887 -
Presence Hallucination in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT04592965 -
Hallucinations in Parkinson's Disease
|
N/A | |
| Completed |
NCT05240339 -
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
|
||
| Recruiting |
NCT03661125 -
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
|
Early Phase 1 |